Skip to main content

Twist Bioscience Corporation (TWST)

NASDAQ: TWST · IEX Real-Time Price · USD
119.75 2.03 (1.72%)
Oct 21, 2021 2:29 PM EDT - Market open
Market Cap5.80B
Revenue (ttm)126.82M
Net Income (ttm)-135.17M
Shares Out48.96M
EPS (ttm)-2.88
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume197,027
Open118.81
Previous Close117.72
Day's Range118.76 - 121.69
52-Week Range74.25 - 214.07
Beta0.75
AnalystsBuy
Price Target120.00 (+0.2%)
Est. Earnings DateNov 26, 2021

About TWST

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; CM...

IndustryBiotechnology
IPO DateOct 31, 2018
CEOEmily Leproust
Employees525
Stock ExchangeNASDAQ
Ticker SymbolTWST
Full Company Profile

Financial Performance

In 2020, TWST's revenue was $90.10 million, an increase of 65.67% compared to the previous year's $54.39 million. Losses were -$139.93 million, 30.0% more than in 2019.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for TWST stock is "Buy." The 12-month stock price forecast is 120.00, which is an increase of 0.21% from the latest price.

Price Target
$120.00
(0.21% upside)
Analyst Consensus: Buy

News

2 Stocks You'll Probably Never Want to Sell

Both are biotech stocks with tremendous long-term opportunities.

Other symbols:VRTX
4 days ago - The Motley Fool

Twist Bioscience and the Broad Institute Create Custom Whole Exome Target Enrichment Panel for Clinical Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

1 week ago - Business Wire

Twist Bioscience Appoints Steffen Hellmold as Senior Vice President, Business Development, Data Storage

SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today ...

1 week ago - Business Wire

3 IPO Cathie Wood Stocks to Buy

It's time to follow the money in three Cathie Wood stocks, while sticking to the price charts in order to enjoy smarter money investments. The post 3 IPO Cathie Wood Stocks to Buy appeared first on Inve...

Other symbols:COINU
2 weeks ago - InvestorPlace

Centogene, Twist Join Forces For Custom Test Kits For Rare Diseases

Centogene NV (NASDAQ: CNTG) and Twist Bioscience Corporation (NASDAQ: TWST) have signed a contract to develop and commercialize custom assay kits for rare diseases. The financial details of the deal wer...

Other symbols:CNTG
2 weeks ago - Benzinga

Twist Bioscience and CENTOGENE to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for Mo...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

Other symbols:CNTG
2 weeks ago - Business Wire

Twist Bioscience Expands Expert Custom Alliance Panel Offering

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

2 weeks ago - Business Wire

Twist Bioscience Appoints Dennis Cho as Senior Vice President, General Counsel and Chief Ethics and Compliance Officer

SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform...

3 weeks ago - Business Wire

Twist Bioscience Internally-Discovered Single Domain Antibody TB202-3 Shows Potent Binding to Multiple Strains of SAR...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) today reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent bindin...

4 weeks ago - Business Wire

Twist Bioscience Collaborates with Deep Learning Experts deepCDR on Antibody Library Design

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

4 weeks ago - Business Wire

Buying This Beaten-Down ETF Could Double Your Money Over the Next 5 Years

It could perhaps deliver a much bigger gain than 100%.

Other symbols:DMTKEDITIBBMRNASTTXBI
4 weeks ago - The Motley Fool

2 Biotech Stocks to Buy Right Now

They both have great growth prospects.

Other symbols:RETA
1 month ago - The Motley Fool

Twist Bioscience Continues Commitment to Deliver Synthetic RNA Controls, now to Fight Delta Plus Variants of COVID-19

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

1 month ago - Business Wire

Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif. & MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience and Adicet Bio collaboration to accelerate the discovery of gamma delta T cell therapies against five undiscl...

Other symbols:ACET
1 month ago - Business Wire

Twist Bioscience, Boehringer Ingelheim Joins Forces For Antibody Research Programs

Twist Bioscience Corporation (NASDAQ: TWST) has announced a broad-based research collaboration with Boehringer Ingelheim International GmbH. The collaboration will use Twist's proprietary antibody libra...

1 month ago - Benzinga

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

SOUTH SAN FRANCISCO, Calif. & INGELHEIM, Germany--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA ...

1 month ago - Business Wire

Twist Bioscience to Present at Baird 2021 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

1 month ago - Business Wire

Twist Bioscience, SomaLogic Team Up For Antibodies, Target Discovery

Twist Bioscience Corporation (NASDAQ: TWST) and SomaLogic announced a partnership to discover novel therapeutic targets and antibodies. Financial and other details of the partnership were not disclosed.

2 months ago - Benzinga

SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies

BOULDER, Colo. & SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (Nasdaq: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, and Twist Biosc...

2 months ago - GlobeNewsWire

Twist Bioscience to Present at UBS Genomics 2.0 and Medtech Innovations Summit

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

2 months ago - Business Wire

Twist Bioscience Stock Falls On Wider Q3 Loss, Sales Beat Estimates; Raises FY21 Guidance

Twist Bioscience Corporation (NASDAQ: TWST) reported a 65% Y/Y increase in its third-quarter revenues to $35 million, beating the Wall Street estimate of $32.27 million, driven by strength in next-gener...

2 months ago - Benzinga

Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates

Twist Bioscience (TWST) delivered earnings and revenue surprises of -7.89% and 7.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Twist Bioscience Reports Third Quarter Fiscal 2021 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

2 months ago - Business Wire

Twist Bioscience Appoints Drug Discovery Leader Melissa Starovasnik, Ph.D., to Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon pl...

2 months ago - Business Wire

Twist Bioscience (TWST) Expected to Beat Earnings Estimates: Should You Buy?

Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research